Novavax (NVAX) has risen sharply, recording gains of 13% in the past 4 weeks. However, the stock has corrected -0.79% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 8.27% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has recorded a 20-day Moving Average of 5.98% and the 50-Day Moving Average is 22.13%.
Novavax (NASDAQ:NVAX): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $7.62 and $7.51 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $7.66. The buying momentum continued till the end and the stock did not give up its gains. It closed at $7.56, notching a gain of 0.13% for the day. The total traded volume was 5,564,686 . The stock had closed at $7.55 on the previous day.
The company Insiders own 3.5% of Novavax shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -17.65% . Institutional Investors own 82.01% of Novavax shares. During last six month period, the net percent change held by insiders has seen a change of -16.33%. In a related news, The director, of Novavax Inc, Evans Gary C had unloaded 18,998 shares at $6.5 per share in a transaction on June 6, 2016. The total value of transaction was $123,487. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Novavax, Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Companys product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Companys lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases, including Middle East respiratory syndrome (MERS).